Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease
Houston, TX, Jun 8, 2023 – (ACN Newswire via SEAPRWire.com) – Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance Treg function, including biologics, today reported additional biomarker and brain imaging results from an open-label proof-of-concept clinical study for COYA 301 in patients with […]